Anondita Medicare Limited (AML) was originally incorporated as a public limited company on March 12, 2024. The company was established to absorb the sole proprietorship business of "M/s Anondita Healthcare," which was originally founded in 1999 by the company's Promoter, Mr. Anupam Ghosh. Operating in the sexual wellness segment of the healthcare industry, AML primarily designs, manufactures, and markets male latex condoms under its flagship consumer brand, "COBRA". Additionally, the company manufactures female condoms under its own patented technology, placing it among a very limited number of global players with such commercial scale and technical capabilities.
The company's business model relies on a diversified and dual-channel market strategy combining institutional direct tenders with a structured trade distribution network. The first vertical targets Institutional and Government Sales, wherein AML supplies male latex condoms directly to central/state government procurement agencies (including the Central Medical Services Society - CMSS) and AIDS Control Societies via competitive bidding. These products are manufactured according to customer-specific technical specifications, packing, and branding. The second vertical comprises Trade and Distribution, which is largely managed through the company’s dedicated subsidiary, Anondita Healthcare and Rubber Products India Limited, supported by Zonal, Regional, and Area Sales Managers coordinating a nationwide web of super-distributors, distributors, and retail points. AML also facilitates direct market penetration of its "COBRA" brand through its authorized distributor, M/s Calcutta Cosmetics, and various wholesalers, with future plans to expand into export markets via UN-qualified public health bids.
Historically, AML acted primarily as a low-margin contract manufacturer (undertaking job work for other major brands) and selectively bid for government contracts, since the typical payment realization cycle of approximately 120 days posed a heavy working capital challenge. However, after strengthening its capital structure through Pre-IPO and IPO fundraising, AML shifted focus towards high-volume government business, bringing its revenue mix to roughly 50% government institutional sales and 50% own-branded sales. Despite this expansion, AML carries extreme client concentration. In Fiscal 2025, the company's top 10 customers contributed ₹6,019.06 Lakhs, which represented an overwhelming 99.46% of its total operational revenue. This extreme concentration has persisted into Fiscal 2026, where a vast majority of its ₹11,169.62 Lakhs in revenue remains heavily dependent on government procurement agencies and AIDS Control Societies.
The company's primary manufacturing facility is strategically located at D-001, Sector 80, Noida, Uttar Pradesh, and covers a total leased built-up area of approximately 1,00,000 square feet (9,290 square meters). Operating under eco-friendly guidelines, the plant utilizes CNG as its clean manufacturing fuel. The facility houses 15 operational manufacturing lines equipped with self-fabricated dipping machinery, high-speed in-house foil printing systems, a 6-color rotogravure printing machine, and advanced testing setups that carry out 100% electronic pinhole testing on every single condom prior to final packaging. In addition, AML is executing a phased capital expenditure program to establish a dedicated, adjoining manufacturing facility for latex and synthetic non-latex (nitrile) female condoms at D-002, Sector 80, Noida.
AML has witnessed substantial capacity growth, elevating its certified annual installed capacity from 5,620.00 Lakhs pieces in Fiscals 2024 and 2025 to 8,690.00 Lakhs pieces (869 million pieces) in Fiscal 2026. This expansion was driven by the commissioning of an additional capacity of 307 million pieces per annum in February 2026. The actual production capacity scaled from 2,199.48 Lakhs pieces in Fiscal 2024 to 2,588.35 Lakhs pieces in Fiscal 2025, and reached 4,321.30 Lakhs pieces in Fiscal 2026. Accordingly, the plant's capacity utilization rate stood at 39.14% in Fiscal 2024, 46.05% in Fiscal 2025, and reached 80.67% in Fiscal 2026. (Installed capacity is computed based on 3 shifts per day, while actual capacity is computed on 2 shifts per day). Moving forward, AML's proposed female condom facility is projected to hold a total capacity of 120 million pieces per annum, with approximately 60 million pieces expected to operationalize during the initial phase.
✍️ Post a Comment